naa a22 4500 510764584 CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1021-5 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1021-5 Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer [Elektronische Daten] [P. Vlachostergios, I. Gioulbasanis, S. Ghosh, C. Tsatsanis, G. Papatsibas, A. Xyrafas, E. Hatzidaki, C. Vasiliou, K. Kamposioras, S. Agelaki, A. Margioris, D. Nasi, V. Georgoulias, C. Papandreou] Objective: Cancer patients usually develop malnutrition which may alter their innate immune system integrity. The aim of this study was to investigate the clinical relevance of chemokine response after lipopolysaccharide (LPS)-stimulation in metastatic non-small cell lung cancer (NSCLC). Methods: Blood samples from metastatic NSCLC patients were incubated with LPS before the onset of systemic therapy. Interleukin (IL)-6 and IL-8 levels at baseline and after LPS-stimulation were measured and the fold change compared to baseline levels was evaluated as the stimulation index for each cytokine per patient. Results were correlated with sex, age, smoking status, histologic subtype, performance status (PS), albumin, Mini Nutritional Assessment (MNA) status and clinical outcomes. Results: Totally 103 patients were evaluated. Mean (±SD) stimulation index was 37.6 (±57.8) for IL-6 and 76.7 (±133.4) for IL-8. The disease control rate after first-line chemotherapy was 44/80 (55%) and the mean (±SD) progression-free survival (PFS) and overall survival (OS) were 4.2 (±3.9) and 9.2 (±1.1) months, respectively. MNA, PS, albumin, IL-6 and IL-8 stimulation indices were univariately associated with PFS and OS. IL-8 stimulation index emerged as an independent predictor of both PFS and OS, along with PS, and albumin levels. Conclusion: The extent of IL-6 and IL-8 stimulation after ex vivo induction with LPS is an important predictor of clinical outcome in metastatic NSCLC patients. Federación de Sociedades Españolas de Oncología (FESEO), 2013 LPS nationallicence IL-6 nationallicence IL-8 nationallicence Lung cancer nationallicence Hospitalization nationallicence Prognosis nationallicence Vlachostergios P. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Gioulbasanis I. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Ghosh S. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada aut Tsatsanis C. Department of Clinical Chemistry, Faculty of Medicine, University of Crete, Heraklion, Greece aut Papatsibas G. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Xyrafas A. Department of Medical Oncology, Faculty of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Greece aut Hatzidaki E. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Vasiliou C. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Kamposioras K. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Agelaki S. Department of Medical Oncology, Faculty of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Greece aut Margioris A. Department of Clinical Chemistry, Faculty of Medicine, University of Crete, Heraklion, Greece aut Nasi D. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Georgoulias V. Department of Medical Oncology, Faculty of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Greece aut Papandreou C. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 903-909 1699-048X 15:11<903 2013 15 12094 https://doi.org/10.1007/s12094-013-1021-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1021-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vlachostergios P. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Gioulbasanis I. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Ghosh S. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada aut NATIONALLICENCE 700 1- Tsatsanis C. Department of Clinical Chemistry, Faculty of Medicine, University of Crete, Heraklion, Greece aut NATIONALLICENCE 700 1- Papatsibas G. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Xyrafas A. Department of Medical Oncology, Faculty of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Greece aut NATIONALLICENCE 700 1- Hatzidaki E. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Vasiliou C. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Kamposioras K. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Agelaki S. Department of Medical Oncology, Faculty of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Greece aut NATIONALLICENCE 700 1- Margioris A. Department of Clinical Chemistry, Faculty of Medicine, University of Crete, Heraklion, Greece aut NATIONALLICENCE 700 1- Nasi D. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 700 1- Georgoulias V. Department of Medical Oncology, Faculty of Medicine, University of Crete, University Hospital of Heraklion, Heraklion, Greece aut NATIONALLICENCE 700 1- Papandreou C. Department of Medical Oncology, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, 41110, Larissa, Greece aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 903-909 1699-048X 15:11<903 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer